Litak is indicated for the treatment of hairy-cell leukaemia.

First-line therapy with a purine analog (cladribine or pentostatin) is recommended for patients with an indication for treatment. Both agents have shown signnificant activity, resulting in durable remissions in patients previously untreated HCL.